CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
Shannon S Zhang1, Alexandria Lee1, Misako Nagasaka1,2
1University of California Irvine School of Medicine, Orange, CA, USA.
Lung Cancer (Auckland, N.Z.)
|April 27, 2023
Summary
Sotorasib, a KRAS G12C inhibitor, showed improved progression-free survival in non-small cell lung cancer (NSCLC) patients compared to docetaxel. Further research is needed for KRAS G12C targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- KRAS G12C mutation occurs in 13% of non-small cell lung cancer (NSCLC) patients.
- Sotorasib is a targeted therapy approved for NSCLC with KRAS G12C mutation.
- Previous trials showed promising response rates and progression-free survival (PFS) for sotorasib.
Purpose of the Study:
- To evaluate the efficacy of sotorasib compared to docetaxel in patients with previously treated, advanced KRAS G12C-mutated NSCLC.
- To assess progression-free survival (PFS) and safety of sotorasib in this patient population.
Main Methods:
- CodeBreaK 200 is a Phase III trial comparing sotorasib to docetaxel.
- Patients had locally advanced or unresectable metastatic KRAS G12C NSCLC, pretreated with chemotherapy and checkpoint inhibitors.
Main Results:
- Sotorasib demonstrated a PFS of 5.6 months versus 4.5 months for docetaxel.
- Adagrasib, another G12C inhibitor, received accelerated FDA approval with a 43% response rate.
- Most adverse events with sotorasib were low-grade, commonly diarrhea and nausea.
Conclusions:
- Sotorasib offers a survival benefit over docetaxel in previously treated KRAS G12C NSCLC.
- The evolving landscape of KRAS G12C inhibitors presents new therapeutic opportunities.
- Further investigation into novel agents and combinations is warranted to overcome resistance and improve outcomes.
Related Concept Videos
02:38The Ras Gene
6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K